Compare Gigacloud Technology Inc (GCT) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Gilead Sciences, Inc. — how do they compare? Gigacloud Technology Inc trades at $38.38 (market cap $1.40B), while Gilead Sciences, Inc. trades at $133.43 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 116.8× Gigacloud Technology Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.
| GCT | GILD | |
|---|---|---|
Market Cap | $1.40B | $163.51B |
Sector | Technology | Health |
52-Week High | $51.80 | $155.80 |
52-Week Low | $20.97 | $108.22 |
Enterprise Value | $1.51B | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $37.85, up 6.91% with strong earnings momentum after beating Q1 2026 EPS estimates. The stock shows bullish technical signals despite mixed indicators, with valuation ratios appearing attractive (P/E 9.49, P/S 1.02). Recent recognition as TIME's World Growth Leader and expanding international presence highlight operational strength.
GCT presents compelling value with robust profitability (32.14% ROE) and consistent earnings beats, though technical overbought conditions and competitive pressures warrant caution. The 66.7% analyst buy rating supports upside potential, but investors should monitor execution risks in international expansion.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
